» Articles » PMID: 29434873

Mechanisms by Which CXCR4/CXCL12 Cause Metastatic Behavior in Pancreatic Cancer

Overview
Journal Oncol Lett
Specialty Oncology
Date 2018 Feb 14
PMID 29434873
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

C-X-C motif chemokine receptor (CXCR) 4/CXCL12 is associated with tumor invasion and metastasis in pancreatic cancer. The present study aimed to investigate the possible mechanisms behind this process by studying the association between the expression of CXCR4 and numerous molecular markers. A total of 60 patients with pancreatic cancer who had been treated with radical surgery between July 2012 and February 2016 were included in the present study. The expression of CXCR4/CXCL12 in primary pancreatic cancer lesions, tissues adjacent to cancerous tissue, non-cancerous pancreatic tissues and in the surrounding lymph nodes was evaluated by immunohistochemistry. Expression levels of four candidate biomarkers [vascular endothelial growth factor-C (VEGF-C), Ki-67, matrix metalloproteinase 2 (MMP-2) and β-catenin] were also evaluated. The correlation between CXCR4 and these four biomarkers was assessed. CXCR4 (CXCL12) expression levels were higher in pancreatic cancer 56.7% (86.7%), paracancerous tissue 50.0% (85.0%) and surrounding lymph nodes 53.3% (80.0%), compared with in normal tissues 18.3% (45.0%). CXCR4 expression was significantly associated with the lymph node metastasis of tumors (P=0.001), pathological type (P=0.037) and tumor-node-metastasis stage (P=0.031). CXCR4 expression exhibited a positive correlation with VEGF-C (r=0.417; P=0.001), Ki-67 (r=0.316; P=0.014), MMP-2 (r=0.284; P=0.028) and β-catenin (r=0.368; P=0.04). Furthermore, logistic regression analysis revealed VEGF-C (β=1.722; P=0.005) and Ki-67 (β=1.196; P=0.047) to be two biomarkers that cause metastasis via CXCR4. CXCR4/CXCL12 is closely associated with tumor grade and lymphatic metastasis. VEGF-C and Ki-67 are two important biomarkers, through which CXCR4 initiates metastatic behavior in pancreatic cancer. Therefore, angiogenesis inhibitors will continue to be effective agents in treating pancreatic cancer.

Citing Articles

Anti-cancer potential of zerumbone in cancer and glioma: current trends and future perspectives.

Soroush A, Pourhossein S, Hosseingholizadeh D, Hjazi A, Shahhosseini R, Kavoosi H Med Oncol. 2024; 41(5):125.

PMID: 38652207 DOI: 10.1007/s12032-024-02327-3.


A Quest for Survival: A Review of the Early Biomarkers of Pancreatic Cancer and the Most Effective Approaches at Present.

Bestari M, Joewono I, Syam A Biomolecules. 2024; 14(3).

PMID: 38540782 PMC: 10968439. DOI: 10.3390/biom14030364.


The Molecular Twin artificial-intelligence platform integrates multi-omic data to predict outcomes for pancreatic adenocarcinoma patients.

Osipov A, Nikolic O, Gertych A, Parker S, Hendifar A, Singh P Nat Cancer. 2024; 5(2):299-314.

PMID: 38253803 PMC: 10899109. DOI: 10.1038/s43018-023-00697-7.


The importance of CXCR4 expression in tumor stroma as a potential biomarker in pancreatic cancer.

Bodoque-Villar R, Padilla-Valverde D, Gonzalez-Lopez L, Ramon Munoz-Rodriguez J, Arias-Pardilla J, Villar-Rodriguez C World J Surg Oncol. 2023; 21(1):287.

PMID: 37697316 PMC: 10496205. DOI: 10.1186/s12957-023-03168-6.


Effect of tocopherol conjugation on polycation-mediated siRNA delivery to orthotopic pancreatic tumors.

Tang S, Kapoor E, Ding L, Yu A, Tang W, Hang Y Biomater Adv. 2022; 145:213236.

PMID: 36512927 PMC: 9852068. DOI: 10.1016/j.bioadv.2022.213236.


References
1.
Bilimoria K, Bentrem D, Merkow R, Tomlinson J, Stewart A, Ko C . Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg. 2007; 205(4):558-63. DOI: 10.1016/j.jamcollsurg.2007.05.009. View

2.
Jiang Y, Li G, Sun B, Zhao X, Zhou Z . Study on the relationship between CXCR4 expression and perineural invasion in pancreatic cancer. Asian Pac J Cancer Prev. 2014; 15(12):4893-6. DOI: 10.7314/apjcp.2014.15.12.4893. View

3.
Xu C, Zhao H, Chen H, Yao Q . CXCR4 in breast cancer: oncogenic role and therapeutic targeting. Drug Des Devel Ther. 2015; 9:4953-64. PMC: 4560524. DOI: 10.2147/DDDT.S84932. View

4.
Chatterjee S, Azad B, Nimmagadda S . The intricate role of CXCR4 in cancer. Adv Cancer Res. 2014; 124:31-82. PMC: 4322894. DOI: 10.1016/B978-0-12-411638-2.00002-1. View

5.
Deng L, Shang Y, Guo S, Liu C, Zhou L, Sun Y . Ran GTPase protein promotes metastasis and invasion in pancreatic cancer by deregulating the expression of AR and CXCR4. Cancer Biol Ther. 2014; 15(8):1087-93. PMC: 4119076. DOI: 10.4161/cbt.29217. View